Aktienanalyse zu Zimmer Biomet Holdings, Inc (ZBH)ZBHZimmer Biomet Holdings, Inc

Zimmer Biomet Holdings, Inc. is a global medical technology company. It designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; CMFT; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its segments include Americas, EMEA, and Asia Pacific. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System and G7 Acetabular System. It also focused on a suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively. Its portfolio features imageless robotics through its ROSA Robotics platform. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Zimmer Biomet is a good buy right now, as it has shown a strong Q2 performance with a non-GAAP EPS of $2.07, exceeding expectations by $0.06, and a revenue growth of 4.8% year-over-year to $2.18 billion. The current price of $94.98 is below the average analyst price target of $100, indicating potential upside. However, the RSI is at 74.53, suggesting it may be overbought, which is a risk to consider.

28 analysts cover ZBH: 18 rate it Buy, 9 Hold and 1 Sell. The average price target is 100.47.